Clinical Trials Logo

Clinical Trial Summary

This study was used to study the diagnostic value of 68Ga-FAPI, a novel fibroblast activating inhibitor, in metastatic adenoid cystic carcinoma(ACC)


Clinical Trial Description

68Ga-FAPI is a positron labeled inhibitor of fibroblast activating protein, which has been widely used in malignant tumor imaging in recent years. Adenoid cystic carcinoma (ACC) is a rare epithelial malignant tumor, which usually originates from salivary glands. Its typical characteristics are long clinical course and high rate of distant metastasis. The purpose of this study was to investigate the clinical value of 68Ga Fapi pet/ct in metastatic adenoid cystic carcinoma. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05499936
Study type Interventional
Source Peking Union Medical College Hospital
Contact Rongxi Wang
Phone +8619800370331
Email pumch_jacobwong@163.com
Status Recruiting
Phase N/A
Start date October 1, 2021
Completion date December 31, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT04973683 - AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer Phase 1
Recruiting NCT05774899 - CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC Phase 1/Phase 2
Completed NCT03990571 - Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma Phase 2
Recruiting NCT04883671 - Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial N/A
Recruiting NCT06118086 - Study of REM-422 in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma Phase 1